LY4256984

DRUG3 trials

Sponsors

Eli Lilly and Company

Conditions

ALS (Amyotrophic Lateral Sclerosis)Amyotrophic Lateral Sclerosis

Phase 1

A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

RecruitingNCT07100119

Eli Lilly and CompanyALS (Amyotrophic Lateral Sclerosis)

Start: 2025-08-05End: 2027-09-01Target: 32Updated: 2026-03-06

A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)

RecruitingNCT07571200

Eli Lilly and CompanyAmyotrophic Lateral Sclerosis

Start: 2026-05-14End: 2029-06-01Target: 32Updated: 2026-08-24

A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

RecruitingNCT07571174

Eli Lilly and CompanyAmyotrophic Lateral Sclerosis

Start: 2026-05-14End: 2029-06-01Target: 32Updated: 2026-08-24